News Amgen scores with new thyroid eye disease formulation Can Amgen's subcutaneous version of Tepezza inject renewed growth into the thyroid eye disease blockbuster?
News Immunovant's thyroid eye disease drug flunks pivotal trials Immunovant shares were sliding today after it reported that FcRn blocker batoclimab failed a pair of phase 3 trials in thyroid eye disease.
News Sanofi linked to takeover bid for Ocular Therapeutix Sanofi is reported to be preparing a move to take control of US biotech Ocular Therapeutix, after an initial bid was rejected last year.
News Ocugen shares fall, despite positive eye disorder trial A trial of Ocugen's gene therapy for sight-robbing disease geographic atrophy (GA) showed efficacy – but still sparked a selloff in its shares.
News Belite plans filing for oral Stargardt drug after phase 3 wi... The first therapy for sight-robbing Stargardt disease could be on the way, as Belite Bio's tinlarebant hits the mark in a phase 3 trial.
News Joy as retinal implant restores sight in geographic atrophy A wireless retinal implant already filed for approval has been shown to restore vision in patients with eye disease geographic atrophy.
News Pulmonary fibrosis drug developer Avalyn files IPO Avalyn Pharma hops on the IPO train, filing to list on the Nasdaq and raise funds for late-stage trials of its inhaled pulmonary fibrosis therapies.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
